Moss Report on Leukemia (CML)
Alternative & Conventional Leukemia (CML) Treatments (2019 Update)
The Moss Reports on leukemia (cancer of the blood) brings you a thorough and up-to-date discussion of the best results with radiation therapy, chemotherapy, immunotherapy, integrative, complementary and alternative treatments for leukemia.
We have separate Moss Reports on the four statistically major forms of leukemia: (Make sure to order the one specific to the type of leukemia you are dealing with.)
What’s New In Leukemia Treatment For 2019
James Allison, PhD, is the head of immunology at the University of Texas M.D. Anderson Cancer Center, Houston. While at the University of California, Berkeley, he invented an important new class of medications called “immune checkpoint inhibitors.” Allison is currently working on combining these medications with cancer-killing viruses, such as Newcastle Disease Virus (NDV) vaccines. These are already available at several foreign clinics.One of the most significant advances of recent years has been the development and FDA approval of an anti-cancer virus vaccine, Reolysin® (pelareorep). The 2019 Moss Report discusses this new medicine and its associated clinical trials, a special process of culturing white blood cells to attack cancer that also showed remarkable, but under-appreciated, results at M.D. Anderson and elsewhere.
Leukemia is a very complex disease. Just as “cancer” itself is a generic term that covers abnormal growths in over 100 different types of tissue, “leukemia” is similarly a constellation of different diseases, all of which share certain characteristics. The most prominent of these is the transformation of an immature blood-forming cell into a malignant one, followed by the proliferation and accumulation of those transformed cells.
Leukemia are also classified into two fundamental divisions-acute and chronic, referring to the speed of their accumulation. The malignant cell type in acute lymphoblastic (or lymphocytic) leukemia (ALL) is derived from primitive white blood cells (WBCs) or even white blood cell precursors. (The predominant malignant cell type in chronic leukemia, on the other hand, resemble more mature cells.)
There is another way of classifying leukemias, by whether they are lymphoblastic or myeloid (or myelogenous). Myeloid leukemias are characterized by an excess of myeloblasts (i.e., immature myelocytes), whereas the more common lymphoblastic leukemia is characterized by an excess of lymphoblasts (i.e., immature lymphocytes). Acute leukemias are defined by the presence of early “blast” forms of white blood cells that become arrested at a primitive stage of their cellular development and do not mature.
Acute lymphoblastic leukemia (ALL) is a form of leukemia in white blood cells are stuck in the early “blast” forms of development and are therefore incapable of maturing or carrying out basic functions. As a result, the bloodstream becomes clogged with immature cells that accumulate, primarily in the bone marrow cavity, ultimately crowding out the bulk of normal cells.
Acute myeloid leukemia (AML) is a malignancy of the bone marrow in which precursors of the white blood cells (i.e., immature bone marrow cells that normally give rise to mature white blood cells) become arrested at a primitive stage in their development. Current thinking is that this malignant transformation is actually a two-stage process, during which an initial mutation occurs at one specific receptor site, which then provides a growth advantage to one particular cellular population, or clone.
Chronic lymphocytic leukemia (CLL) is a kind of cancer in which too many otherwise necessary lymphocytes are produced by the bone marrow. But these are not normal disease-fighting cells. The lymphocytes produced in CLL have a flaw in their DNA that confers an inbuilt survival advantage to them-in fact, makes them virtually immortal. While normal cells are pre-programmed to die at a certain rate, the lymphocytes in CLL lack this ability. Instead, they remain viable indefinitely and consequently they accumulate in the blood, bone marrow, and lymphatic system, ultimately in enormous numbers.
In CLL, while the lymphocytes produced by the bone marrow for all intents and purposes look like normal lymphocytes, they are immunologically immature and are thus unable to function effectively in the body’s defense. The overall result is that the number of lymphocytes in the bloodstream and bone marrow soars – yet, unlike in acute childhood leukemias, it does so relatively slowly, and without impeding the concurrent production of normal blood cells by the bone marrow.
Chronic myeloid leukemia (CML) affects myeloid tissue in the bone marrow, the tissue which actually gives rise to the white blood cells. Cells in CML may appear at first entirely normal. Sometimes a microscopic chromosomal examination is necessary to establish that the white cell proliferation in the blood is due to CML rather than-as may happen-due to an infection.
The essential feature of CML is a vastly increased white cell count. Normally, a person’s white blood cell (WBC) count is between 5,000 and 10,000, but in CML this count can rise spectacularly, topping 50,000 to 500,000.
Discounts and Savings Available
Purchase both the E-Book and
Printed Moss Report and save $100.*
Purchase a Moss Report and
Schedule a Consultation and save $100.*
If you are a Medical Professional and refer patients to Moss Reports, click here find out more about our advocate program.
*Discounts applied when purchased together at check-out.
Table of Contents
- A QUICK GUIDE TO CAM CANCER TREATMENTS
- GREEN LIGHT TREATMENTS: WELL RESEARCHED APPROACHES
- AMBER LIGHT TREATMENTS FOR CANCER: EFFICACY AND SAFETY STILL UNCLEAR
- RED LIGHT TREATMENTS: POORLY RESEARCHED (OR DOWNRIGHT DANGEROUS)
- CONVENTIONAL TREATMENT SECTION
- TYPES OF LEUKEMIA
- EPIDEMIOLOGY OF CML
- BACKGROUND AND HISTORY
- MOLECULAR BIOLOGY
- PHILADELPHIA CHROMOSOME
- HEMATOLOGICAL RESPONSE (HR)
- COMPLETE HEMATOLOGICAL RESPONSE (CHR)
- CYTOGENETIC RESPONSE
- TREATMENT OF CML
- EMERGING THERAPIES
- GRAFT-VS.-HOST DISEASE (GVHD)
- RISKS OF HCT
- NON-MYOABLATIVE TRANSPLANTATION
- TRADITIONAL CHEMOTHERAPY
- LOW-DOSE INTERFERON
- FINDING A CML SPECIALIST
- TOP SUPPLEMENTS (THE SHORT LIST)
- ANTI-CANCER PLAN ON A TIGHT BUDGET
- ANTI-CANCER RECIPES
- THE HALLMARKS OF CANCER
- A NEW MODEL FOR CANCER TREATMENT
- INNOVATIVE SURGERY
- INNOVATIVE RADIATION THERAPY
- INNOVATIVE CHEMOTHERAPY
- NAUSEA AND VOMITING
- MOUTH SORES (STOMATITIS)
- ZINC SULFATE
- NERVE PAIN
- HAIR LOSS
- PICKLE JUICE REMEDY
- CHEMOSENSITIVITY TESTING
- TARGETED THERAPIES
- PRECISION MEDICINE INITIATIVE
- ANTI-ANGIOGENESIS DRUGS
- MOLECULAR AND GENOMIC TESTING
- CIRCULATING TUMOR CELLS (CELLSEARCH)
- MONOCLONAL ANTIBODIES
- IMMUNE CHECKPOINT BLOCKADE (ICB)
- CANCER STEM CELLS (CSCS)
- DIETARY COMPOUNDS THAT KILL CANCER STEM CELLS (CSCS)
- PHYSICAL ACTIVITY AND EXERCISE
- FASTING AND THE KETOGENIC DIET
- A COST-FREE WAY TO PREVENT CANCER RECURRENCES
- CALORIC RESTRICTION
- PRACTICAL NOTES ON FASTING
- TOP TEN SUPPLEMENTS (THE EXPOSITION)
- FOOD AND CANCER PREVENTION
- VITAMINS, MINERALS & ANTIOXIDANTS
- THE CONCURRENT USE DEBATE
- CONCURRENT USE OF ANTIOXIDANTS AND RADIATION
- HERBS, SPICES AND BOTANICALS
- SOUND, LIGHT AND ELECTRICITY
- CANCER IMMUNOTHERAPY
- VIRAL THERAPY (ONCOLYTIC VIRUSES)
- DRUGS NEW AND OLD
- INNOVATIVE CANCER CLINICS
- FINDING AN INTEGRATIVE PHYSICIAN
- INTEGRATIVE ONCOLOGY DEPARTMENTS
- AMERICAN CLINICS
- INTERNATIONAL CLINICSSUPPLEMENTS AND SURGERY
- CAM AND FATIGUE
- POPULAR BUT UNLIKELY TREATMENTS